Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlo Messina

Showing results (81-90 of 106) with videos related to

Pageof 11
Sort By:
Clinical Genitourinary Cancer|May 22, 2024
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)Elisabetta Gambale, Marco Maruzzo, Carlo Messina, et al.
Cancer Immunology, Immunotherapy : CII|February 14, 2026
Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25Giandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
Targeted Oncology|May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
Frontiers in Immunology|June 29, 2026
Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) studyGiandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
The Oncologist|November 20, 2025
Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25)Giandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
Clinical Genitourinary Cancer|May 1, 2026
Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 studyGiandomenico Roviello, Martina Catalano, Elisabetta Gambale, et al.
The Journal of Clinical Investigation|December 25, 2019
Genomics of lethal prostate cancer at diagnosis and castration resistanceJoaquin Mateo, George Seed, Claudia Bertan, et al.
Minerva Urology and Nephrology|April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2024
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 studyCarlo Messina, Martina Catalano, Giandomenico Roviello, et al.
The Oncologist|August 1, 2020
Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise CentersLucia Nappi, Margaret Ottaviano, Pasquale Rescigno, et al.
Pageof 11

Showing results (81-90 of 106) with videos related to

Sort By:
Pageof 11
Clinical Genitourinary Cancer|May 22, 2024
Neutrophil-to-Eosinophil Ratio Predicts the Efficacy of Avelumab in Patients With Advanced Urothelial Carcinoma Enrolled in the MALVA Study (Meet-URO 25)Elisabetta Gambale, Marco Maruzzo, Carlo Messina, et al.
Cancer Immunology, Immunotherapy : CII|February 14, 2026
Site and number of metastases predict outcomes in avelumab maintenance for advanced UC: results from meet-URO 25Giandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
Targeted Oncology|May 5, 2024
Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)Ondřej Fiala, Sebastiano Buti, Aristotelis Bamias, et al.
Frontiers in Immunology|June 29, 2026
Effectiveness and safety of avelumab maintenance in patients aged ≥75 years with advanced urothelial cancer: a sub-analysis of the meet-URO 25 (MALVA) studyGiandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
The Oncologist|November 20, 2025
Real-world effectiveness of Avelumab maintenance in advanced urothelial carcinoma: results from the Italian multicenter MALVA study (Meet-URO 25)Giandomenico Roviello, Elisabetta Gambale, Irene De Gennaro Aquino, et al.
Clinical Genitourinary Cancer|May 1, 2026
Concomitant medications and survival outcomes in patients receiving avelumab maintenance for advanced urothelial carcinoma: sub analysis of Meet-URO 25 studyGiandomenico Roviello, Martina Catalano, Elisabetta Gambale, et al.
The Journal of Clinical Investigation|December 25, 2019
Genomics of lethal prostate cancer at diagnosis and castration resistanceJoaquin Mateo, George Seed, Claudia Bertan, et al.
Minerva Urology and Nephrology|April 23, 2026
Real-world comparison of the effectiveness and safety of immune-based combinations in elderly patients with advanced renal cell carcinoma (ARON-1 study)Marco Maruzzo, Alexandr Poprach, Sebastiano Buti, et al.
Cancer Immunology, Immunotherapy : CII|July 2, 2024
Long-term responders to nivolumab in previously treated advanced renal cell carcinoma: a sub-analysis of meet-URO15 studyCarlo Messina, Martina Catalano, Giandomenico Roviello, et al.
The Oncologist|August 1, 2020
Management of Germ Cell Tumors During the Outbreak of the Novel Coronavirus Disease-19 Pandemic: A Survey of International Expertise CentersLucia Nappi, Margaret Ottaviano, Pasquale Rescigno, et al.
Pageof 11